Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.51

-1.3%

Jan 16 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who started this subject	11/26/2000 3:55:50 PM
From: Pseudo Biologist	Read Replies (2) of 52153

Interesting article from Forbes: forbes.com A few years ago biotech companies dismissed their enemies as Greenpeacers and Luddites. Not any more. Now there's a widely supported moratorium on new imports of genetically modified foods in Europe and a very similar sentiment running through the middle of America. Today, Monsanto; tomorrow, Merck. "Your heydays are over, that's what I tell the drug companies," says Uwe Reinhardt, a medical economist at Princeton University. "I think their 18% rate of return on assets will be pushed to a more normal level. Just watch the slaughter." ... ... If AIDS-fighting proteases cost $14,000 a year in the U.S. but something close to manufacturing costs—$2,000 a year—in Africa, that could be seen as a humanitarian gesture. But at some point uninsured, unprosperous patients in the U.S. want to receive the humanitarian rate. Etc. PB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next